Ulus Ali Şanlı

767 total citations
49 papers, 460 citations indexed

About

Ulus Ali Şanlı is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ulus Ali Şanlı has authored 49 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 16 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ulus Ali Şanlı's work include Retinoids in leukemia and cellular processes (6 papers), Cancer Diagnosis and Treatment (6 papers) and HER2/EGFR in Cancer Research (5 papers). Ulus Ali Şanlı is often cited by papers focused on Retinoids in leukemia and cellular processes (6 papers), Cancer Diagnosis and Treatment (6 papers) and HER2/EGFR in Cancer Research (5 papers). Ulus Ali Şanlı collaborates with scholars based in Türkiye, United States and Japan. Ulus Ali Şanlı's co-authors include Rüçhan Uslu, Bülent Karabulut, Erdem Göker, Burçak Karaca, Canfeza Sezgin, Harika Atmaca, Selim Uzunoğlu, Çiğdem Erten, Yüksel Küçükzeybek and Mustafa Gül and has published in prestigious journals such as Journal of Clinical Oncology, Gynecologic Oncology and BMJ Open.

In The Last Decade

Ulus Ali Şanlı

43 papers receiving 447 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulus Ali Şanlı Türkiye 13 186 172 97 74 46 49 460
Fadel Bennani Ireland 7 96 0.5× 144 0.8× 69 0.7× 46 0.6× 42 0.9× 20 398
Shian‐Shiang Wang Taiwan 14 378 2.0× 104 0.6× 203 2.1× 189 2.6× 141 3.1× 82 721
Yoshiaki Okuno Japan 20 231 1.2× 248 1.4× 78 0.8× 80 1.1× 57 1.2× 41 796
Neeraj Rastogi India 16 207 1.1× 114 0.7× 120 1.2× 82 1.1× 165 3.6× 41 578
Krisha Desai United States 7 122 0.7× 191 1.1× 48 0.5× 100 1.4× 48 1.0× 16 403
Dae–Yong Hwang South Korea 16 130 0.7× 340 2.0× 195 2.0× 105 1.4× 162 3.5× 52 684
Hillard Lazarus United States 11 220 1.2× 163 0.9× 44 0.5× 41 0.6× 32 0.7× 17 699
Jianhui Yang China 14 367 2.0× 169 1.0× 136 1.4× 257 3.5× 72 1.6× 46 697
Tiantian Zhang China 12 191 1.0× 105 0.6× 91 0.9× 38 0.5× 44 1.0× 48 499
Frederick Lansigan United States 18 170 0.9× 350 2.0× 69 0.7× 53 0.7× 22 0.5× 105 992

Countries citing papers authored by Ulus Ali Şanlı

Since Specialization
Citations

This map shows the geographic impact of Ulus Ali Şanlı's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulus Ali Şanlı with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulus Ali Şanlı more than expected).

Fields of papers citing papers by Ulus Ali Şanlı

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulus Ali Şanlı. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulus Ali Şanlı. The network helps show where Ulus Ali Şanlı may publish in the future.

Co-authorship network of co-authors of Ulus Ali Şanlı

This figure shows the co-authorship network connecting the top 25 collaborators of Ulus Ali Şanlı. A scholar is included among the top collaborators of Ulus Ali Şanlı based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulus Ali Şanlı. Ulus Ali Şanlı is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Şanlı, Ulus Ali, et al.. (2024). Response rates of pazopanib therapy in metastatic soft tissue sarcoma using real‑world data. Oncology Letters. 29(3). 102–102. 1 indexed citations
3.
Lorusso, Domenica, Vicky Makker, Antonio Casado, et al.. (2022). 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. International Journal of Gynecological Cancer. 32. A102–A102. 1 indexed citations
4.
Oruç, Nevin, Deniz Yalman, Denız Nart, et al.. (2020). Ege Üniversitesi hastanesi veri tabanındaki pankreas kanserlerinin epidemiyolojik ve genel sağkalım özellikleri. Ege Tıp Dergisi. 25–32. 1 indexed citations
5.
Dane, Faysal, Şuayib Yalçın, Mustafa Beneklı, et al.. (2020). Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. BMJ Open. 10(3). e027665–e027665. 9 indexed citations
6.
Akman, Levent, Nuri Yıldırım, Mustafa Coşan Terek, et al.. (2019). Korpus uteri kanserlerinin epidemiyoloji ve sağ kalım özellikleri. Ege Tıp Dergisi. 33–38. 1 indexed citations
7.
Yıldırım, Nuri, Levent Akman, Necmettin Özdemir, et al.. (2019). Over kanserinin epidemiyolojisi ve genel sağ kalım özellikleri. Ege Tıp Dergisi. 44–49. 1 indexed citations
8.
Haydaroğlu, Ayfer, Zeynep Özsaran, Ulus Ali Şanlı, et al.. (2019). Ege Ünıversıtesı Hastanesınde jinekolojik kanserlerin epidemiyolojik ve genel sağ kalım özellikleri. Ege Tıp Dergisi. 26–32. 1 indexed citations
9.
Çakar, Burcu & Ulus Ali Şanlı. (2018). Kolorektal Kanserlerde Prognostik Faktörler. 11(4). 52–57. 1 indexed citations
10.
Özveren, Ahmet, et al.. (2015). Prognostic role of neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with docetaxel.. Journal of Clinical Oncology. 33(15_suppl). e16050–e16050. 2 indexed citations
11.
Şanlı, Ulus Ali, et al.. (2013). Algorithms for scheduling of chemotherapy plans. Computers in Biology and Medicine. 43(12). 2103–2109. 34 indexed citations
12.
Küçükzeybek, Yüksel, Burçak Karaca, Bülent Karabulut, et al.. (2009). Trastuzumab Induced Maculopapular Skin Reactions Localized on the Left Forearm and Arm: A Case Report. Turkiye Klinikleri Tip Bilimleri Dergisi. 29(6). 1743–1746. 2 indexed citations
13.
Atmaca, Harika, Burçak Karaca, Selim Uzunoğlu, et al.. (2009). Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. European Cytokine Network. 20(3). 121–130. 22 indexed citations
14.
Göksel, Gamze, Osman Zekioğlu, Murat Kapkaç, et al.. (2008). Comparison of Inflammatory Breast Cancer and Noninflammatory Breast Cancer in Western Turkey. Medical Principles and Practice. 17(6). 475–480. 3 indexed citations
15.
Küçükzeybek, Yüksel, Mustafa Gül, Çiğdem Erten, et al.. (2008). Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. Journal of Experimental & Clinical Cancer Research. 27(1). 37–37. 25 indexed citations
16.
Sezgin, Canfeza, Bülent Karabulut, Rüçhan Uslu, et al.. (2005). Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scandinavian Journal of Gastroenterology. 40(12). 1486–1492. 28 indexed citations
17.
Burak, Zeynep, et al.. (2003). 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.. PubMed. 44(9). 1394–401. 36 indexed citations
18.
Sezgin, Canfeza, Ulus Ali Şanlı, Rüçhan Uslu, & Erdem Göker. (2002). Arsenic Trioxide Has Additive Cytotoxic Effects on MCF-7 Breast Cancer Cell Line With Taxanes. TURKISH JOURNAL OF MEDICAL SCIENCES. 32(6). 439–444. 10 indexed citations
19.
Saydam, Güray, et al.. (2002). Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leukemia Research. 26(4). 391–398. 21 indexed citations
20.
Şanlı, Ulus Ali, Rüçhan Uslu, Bülent Karabulut, et al.. (2002). Which dosing scheme is suitable for the taxanes? anin vitro model. Archives of Pharmacal Research. 25(4). 550–555. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fadel Bennani Breakdown of academic impact, for papers by Shian‐Shiang Wang Breakdown of academic impact, for papers by Yoshiaki Okuno Breakdown of academic impact, for papers by Neeraj Rastogi Breakdown of academic impact, for papers by Krisha Desai Breakdown of academic impact, for papers by Dae–Yong Hwang Breakdown of academic impact, for papers by Hillard Lazarus Breakdown of academic impact, for papers by Jianhui Yang Breakdown of academic impact, for papers by Tiantian Zhang Breakdown of academic impact, for papers by Frederick Lansigan
Rankless by CCL
2026